About Total Blood Profile (TBP)
Revolutionary diagnostic platform that delivers results in under one hour from whole blood at point of care.
Total Blood Profile (TBP) is commercialising a revolutionary diagnostic platform developed by the Monash University Centre for Biospectroscopy (MCfB). Our exclusive Sub-License is with Biotech Resources (Aust) Pty Ltd who have an exclusive Commercialisation Agreement with Monash University that covers the development of a vibrational spectroscopy tool for the rapid detection of pathogens and biomarkers in bodily fluids. The IP is protected by a family of four international patents with the first two now granted in the US.
The platform is rapid, highly accurate and more cost effective than current technologies. It requires minimal training and unlike other tests it does not rely on culturing, chemical reagents, microscopy or other laboratory-based skills to diagnose disease or quantitatively detect biomarkers.
Proof of concept has been achieved with validated data for the diagnosis of a range of pathogens including parasites (malaria), viruses (hepatitis B&C) and the fungi and bacteria that cause sepsis.
Field studies for malarial detection have been completed in Thailand, PNG and Laos. A hospital study for sepsis is being undertaken at The Alfred Hospital in Melbourne Australia.
Diagnosing Sepsis - A disease which kills 8 million people
Our first test to market will be the direct detection of the bacteria and fungi that cause sepsis, a disease that kills over 8 million people worldwide every year.
This test will be conducted at point-of-care in under one hour from whole blood without blood culturing.
An Observational Study is currently being conducted at the Alfred Hospital to provide proof of concept in a point-of-care setting.
Current tests for sepsis take 1-6 days and are subject to a high percentage of false positives. They are too slow and unreliable to guide best practice clinical decisions and often lead to inappropriate treatment.
One million Americans are diagnosed with sepsis each year, 250,000 will die. We estimate the total addressable market for TBP’s sepsis diagnostic is $2.4 billion USD p.a.
Antibiotic Susceptibility Test (AST)
In addition to our sepsis test, we have proof of concept for our Antibiotic Susceptibility Test (AST) that detects resistance to a broad range of antibiotics in under two hours from positive blood cultures (patent pending).
Current AST test times of up to 48 hours lead to significant delay of effective therapy and has critical impact on patients’ survival chances.
Our rapid test can discriminate between resistant and susceptible strains of bacteria when looking at vancomycin, daptomycin and methicillin resistance.
The global antimicrobial susceptibility testing (AST) market was estimated to be worth USD 2.71 Billion in 2017 and is growing at a CAGR of 5.1%.
Biomarker Detection in Bodily Fluids
The diagnostic portfolio has been extended to biomarker detection in bodily fluids.
Proof-of-concept in the lab shows the ability to quantitatively detect clinically relevant biomarkers in urine associated with diabetes and kidney disease.
Our diagnostic quantitatively tests for protein biomarkers that are indicators of early stage chronic kidney disease (CKD) in asymptomatic patients. The test aims to provide results to clinicians in a single patient visit eliminating the need for external pathology and multiple patient visits.
CKD is affects 15% of the U.S (30 million people), however, 96% of those with early kidney disease don’t know they have it.
The global Urinalysis market was estimated at USD 1.32 Billion in 2016 and is growing at a CAGR of 7.6%.
TBP has completed a comprehensive Regulatory Strategy and Product Deployment Strategy that details a clear path to market with all activities/deliverables costed. TBP is has been designated by the ATO as an Early Stage Innovation Company (ESIC) providing investors with potential tax advantages.
Director: Total Blood Profile Pty Ltd
M: + 61 404 878 213